InsiderTrades.com logo
Will this $2 AI stock double overnight?
From Behind the Markets   |   Ad
It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!
Click here to learn more >>>

PAR Insider Trading

Insider Ownership Percentage: 13.00%
Insider Buying (Last 12 Months): A$86,013.01
Insider Selling (Last 12 Months): A$0.00

Paradigm Biopharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Paradigm Biopharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Paradigm Biopharmaceuticals Share Price & Price History

Current Price: A$0.00
Price Change: +0.30 (1.20%)
As of 05/13/2020 01:00 AM ET

This chart shows the closing price history over time for PAR up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Will this $2 AI stock double overnight?
From Behind the Markets   |   Ad
It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!
Click here to learn more >>>

Paradigm Biopharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/30/2023Paul RennieInsiderIssued349,500A$0.39A$136,305.00
5/18/2023Helen FisherInsiderBuy10,204A$0.98A$10,020.33
5/12/2023Paul RennieInsiderBuy73,851A$1.03A$75,992.68
3/8/2022Paul RennieInsiderBuy48,167A$1.05A$50,623.52
1/25/2022Donna SkerrettInsiderBuy375,000A$1.89A$708,750.00
See Full Table
How to camouflage a factory of 53,000 workers
From Stansberry Research   |   Ad
"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."
Get the full story here.

SEC Filings (Institutional Ownership Changes) for Paradigm Biopharmaceuticals (ASX:PAR)

15.42% of Paradigm Biopharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Paradigm Biopharmaceuticals logo
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulfate sodium drugs in the injectable form for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.
Read More on Paradigm Biopharmaceuticals

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

1,805,207 shs

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.92

Who are the company insiders with the largest holdings of Paradigm Biopharmaceuticals?

Paradigm Biopharmaceuticals' top insider investors include:
  1. Helen Fisher (Insider)
  2. Paul Rennie (Insider)
Learn More about top insider investors at Paradigm Biopharmaceuticals.
Will this $2 AI stock double overnight?
From Behind the Markets   |   Ad
It's a tiny AI company fighting for a big piece of a $20 Billion Pentagon contract. What's more, this groundbreaking firm is trading for less than $2 a share!
Click here to learn more >>>